---
title: "Baili Tianheng's iza-bren late-stage triple-negative breast cancer Phase III clinical study achieved dual endpoints of PFS and OS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276580080.md"
description: "Baili Tianheng's independently developed EGFR×HER3 dual antibody ADC (iza-bren) successfully achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in a Phase III clinical trial targeting locally advanced or metastatic triple-negative breast cancer"
datetime: "2026-02-23T09:01:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276580080.md)
  - [en](https://longbridge.com/en/news/276580080.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276580080.md)
generator: "portal-rs"
---

# Baili Tianheng's iza-bren late-stage triple-negative breast cancer Phase III clinical study achieved dual endpoints of PFS and OS

Recently, the globally first, innovative, and only EGFR×HER3 dual-target ADC (iza-bren) independently developed by BaiLi TianHeng has successfully achieved the predefined interim analysis for both PFS (Progression-Free Survival) and OS (Overall Survival) as dual primary endpoints in a Phase III clinical trial (Study Number: BL-B01D1-307) targeting locally advanced or metastatic triple-negative breast cancer (TNBC)

### Related Stocks

- [688177.CN](https://longbridge.com/en/quote/688177.CN.md)

## Related News & Research

- [BIDU-SW  to Pursue Dual Primary Listing on HKEX and Nasdaq Starting Next Tue](https://longbridge.com/en/news/297102765.md)
- [Infrastructure Dividend Split Corp declares August Class A distribution of $ 0.15 per share](https://longbridge.com/en/news/296799113.md)
- ["Chinese AI Demand Is Very Real": Goldman One-Delta Desk Favors Hardware As Cheaper Inference Is Unlocking More Usage](https://longbridge.com/en/news/297208026.md)
- [SP Group corrects disclosure, names Schur Finance as buyer of 31,500 shares at DKK 485](https://longbridge.com/en/news/296803384.md)
- [Oddo BHF AIF buys 9,004 Voyageurs du Monde shares at EUR 178.45 each](https://longbridge.com/en/news/296791283.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**